$SLRN
ACELYRIN, Inc. Stock $slrn

$slrn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000196291824000106 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.33M	$16.64M	$12.67M
YoY Change	-37.94%	31.4%	482.08%
% of Gross Profit
Research & Development	$31.61M	$76.38M	$30.03M
YoY Change	-57.6%	154.35%	136.27%
% of Gross Profit
Depreciation & Amortization	$106.0K	$116.0K	$27.00K
YoY Change	165.0%	329.63%
% of Gross Profit
Operating Expenses	$54.75M	$93.03M	$42.70M
YoY Change	-42.02%	117.88%	186.82%
Operating Profit	-$54.75M	-$93.03M	-$42.70M
YoY Change	-42.02%	117.88%
Interest Expense	$7.535M	$8.447M	$16.83M
YoY Change	-28.25%	-49.81%	3974.82%
% of Operating Profit
Other Income/Expense, Net	-$1.336M	-$1.094M	-$172.0K
YoY Change	6931.58%	536.05%	17100.0%
Pretax Income	-$48.55M	-$85.67M	-$26.04M
YoY Change	-42.16%	229.01%	79.9%
Income Tax
% Of Pretax Income
Net Earnings	-$48.55M	-$85.67M	-$26.04M
YoY Change	-42.16%	229.01%	79.9%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.49	-$0.86	-$0.40
Diluted Earnings Per Share	-$0.49	-$0.86	-$0.40
COMMON SHARES
Basic Shares Outstanding	99.81M shares	99.03M shares	65.21M shares
Diluted Shares Outstanding	99.84M shares	99.16M shares	65.21M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$562.4M	$635.2M	$823.0M
YoY Change	-28.67%	-22.81%
Cash & Equivalents	$216.3M	$128.2M	$556.2M
Short-Term Investments	$346.0M	$507.0M	$266.8M
Other Short-Term Assets	$4.146M	$7.500M	$6.723M
YoY Change	-2.56%	11.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$596.6M	$648.3M	$829.8M
YoY Change	-24.92%	-21.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.700M	$1.509M	$1.972M
YoY Change	-20.15%	-23.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.101M	$868.0K	$2.077M
YoY Change	-55.64%	-58.21%
Total Long-Term Assets	$21.72M	$3.478M	$5.334M
YoY Change	271.24%	-34.8%
TOTAL ASSETS
Total Short-Term Assets	$596.6M	$648.3M	$829.8M
Total Long-Term Assets	$21.72M	$3.478M	$5.334M
Total Assets	$618.3M	$651.7M	$835.1M
YoY Change	-22.76%	-21.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.55M	$40.72M	$9.127M
YoY Change	-6.16%	346.17%
Accrued Expenses	$65.17M	$40.60M	$21.33M
YoY Change	40.33%	90.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$83.47M	$82.45M	$32.75M
YoY Change	24.84%	151.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.558M	$1.069M	$1.309M
YoY Change	423.8%	-18.33%
Total Long-Term Liabilities	$6.558M	$1.069M	$1.309M
YoY Change	423.8%	-18.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$83.47M	$82.45M	$32.75M
Total Long-Term Liabilities	$6.558M	$1.069M	$1.309M
Total Liabilities	$90.03M	$83.52M	$34.06M
YoY Change	32.18%	145.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$657.9M	-$609.4M	-$309.6M
YoY Change	67.19%	96.83%
Common Stock	$1.000K	$1.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$528.3M	$568.2M	$801.1M
YoY Change
Total Liabilities & Shareholders Equity	$618.3M	$651.7M	$835.1M
YoY Change	-22.76%	-21.96%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$48.55M	-$85.67M	-$26.04M
YoY Change	-42.16%	229.01%	79.9%
Depreciation, Depletion And Amortization	$106.0K	$116.0K	$27.00K
YoY Change	165.0%	329.63%
Cash From Operating Activities	-$78.76M	-$46.28M	-$31.62M
YoY Change	101.31%	46.35%	10.3%
INVESTING ACTIVITIES
Capital Expenditures	$297.0K	$814.0K	$1.761M
YoY Change	50.76%	-53.78%
Acquisitions
YoY Change
Other Investing Activities	$166.2M	-$88.37M	-$266.1M
YoY Change	-223.45%	-66.79%	159.38%
Cash From Investing Activities	$165.9M	-$89.18M	-$267.9M
YoY Change	-223.05%	-66.71%	161.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.006M	-289.0K	566.5M
YoY Change	-301.6%	-100.05%	353.27%
NET CHANGE
Cash From Operating Activities	-78.76M	-46.28M	-31.62M
Cash From Investing Activities	165.9M	-89.18M	-267.9M
Cash From Financing Activities	1.006M	-289.0K	566.5M
Net Change In Cash	88.12M	-135.7M	267.0M
YoY Change	-150.52%	-150.85%	-4347.14%
FREE CASH FLOW
Cash From Operating Activities	-$78.76M	-$46.28M	-$31.62M
Capital Expenditures	$297.0K	$814.0K	$1.761M
Free Cash Flow	-$79.06M	-$47.09M	-$33.38M
YoY Change	101.06%	41.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1069000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1194000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	83521000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-85672000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-62000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	556169000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	128735000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1348000	usd
CY2024Q2	slrn	Temporary Equity Convertible Conversion Ratio TemporaryEquityConvertibleConversionRatio	1
	us-gaap	Net Income Loss NetIncomeLoss	-120600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-202500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-120600000	usd
CY2023Q4	slrn	Asset Acquisition Separately Recognized Transactions Severance Payable Current AssetAcquisitionSeparatelyRecognizedTransactionsSeverancePayableCurrent	300000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	86353000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30337000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	15640000	usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	10415000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	911000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	10291000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94000	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99570421	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99570421	shares
CY2023Q2	slrn	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock In Connection With Initial Public Offering ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithInitialPublicOffering	40743522	shares
CY2023Q2	slrn	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	396593000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	396593000	usd
CY2023Q2	slrn	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures And Decrease For Tax Withholding Obligation StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeituresAndDecreaseForTaxWithholdingObligation	8325000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8501000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-26039000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	44000	usd
CY2023Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	801066000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-120645000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-202489000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	7000000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	133057000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	171000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1369000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	15000	usd
	slrn	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	-2995000	usd
	slrn	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	3246000	usd
	slrn	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	-2353000	usd
	slrn	Increase Decrease In Prepaid Expenses And Other Assets Noncurrent IncreaseDecreaseInPrepaidExpensesAndOtherAssetsNoncurrent	-2129000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1198000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1120000	usd
	slrn	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-319000	usd
	slrn	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	7733000	usd
	slrn	Increase Decrease In Accrued Compensation And Other Current Liabilities IncreaseDecreaseInAccruedCompensationAndOtherCurrentLiabilities	-1354000	usd
	slrn	Increase Decrease In Accrued Compensation And Other Current Liabilities IncreaseDecreaseInAccruedCompensationAndOtherCurrentLiabilities	-2064000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-125000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	40000	usd
	slrn	Increase Decrease In Severance Liability IncreaseDecreaseInSeveranceLiability	164000	usd
	slrn	Increase Decrease In Severance Liability IncreaseDecreaseInSeveranceLiability	2291000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103574000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56949000	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	7000000	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	10007000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	491965000	usd
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.5071
CY2024Q2	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent
CY2024Q2	slrn	Severance Liability Current SeveranceLiabilityCurrent	1134000	usd
CY2023Q4	slrn	Severance Liability Current SeveranceLiabilityCurrent	970000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	82452000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85159000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1177748000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1144893000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-167000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	162000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-609364000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-488719000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	568218000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	656337000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	651739000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	742690000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	76382000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30030000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16643000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12666000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	93025000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	42696000	usd
	us-gaap	Operating Expenses OperatingExpenses	175799000	usd
	us-gaap	Operating Expenses OperatingExpenses	222529000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-93025000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-42696000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-175799000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-222529000	usd
CY2024Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2023Q2	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	10144000	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	10291000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	8447000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6685000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	17597000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9984000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1094000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-172000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37557000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-235000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-85672000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-26039000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-120645000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-202489000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-62000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	44000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-329000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	130000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-62000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	44000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-329000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	130000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85734000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25995000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120974000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-202359000	usd
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99161710	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99161710	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65210117	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65210117	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98537685	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98537685	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	656337000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20163000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2807000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-34973000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-267000	usd
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	644067000	usd
CY2024Q2	slrn	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures And Decrease For Tax Withholding Obligation StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeituresAndDecreaseForTaxWithholdingObligation	1937000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10174000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1289000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	359000	usd
CY2024Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	568218000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102862000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	128735000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7139000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-176450000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	86000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	40743522	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	396593000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-143352000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	47354000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	573644000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	266112000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	491465000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	47773000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	6082000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	869000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1999000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11713000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-220331000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2518000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8325000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	574664000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2518000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	566339000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-89343000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	289059000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218097000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267110000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128754000	usd
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	40743522	shares
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	396593000	usd
	slrn	Offering Costs Incurred During Noncash Or Partial Noncash Transaction OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
	slrn	Offering Costs Incurred During Noncash Or Partial Noncash Transaction OfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction	530000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	301000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2024Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	37000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-202500000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-609400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56900000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	635800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates estimates and assumptions, including but not limited to those related to the fair value of its derivative tranche liability, the fair value of its common stock, stock-based compensation expense, accruals for research and development expenses, valuation of deferred tax assets, and uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash and short-term marketable securities are financial instruments that potentially subject the Company to concentrations of credit risk. As of June 30, 2024 and December 31, 2023, cash consists of cash deposited with one financial institution, and account balances exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of this institution.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investments in money market funds, U.S. Treasury obligations, corporate debt obligations, and federal agency obligations, which can be subject to certain credit risks. The Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its financial instruments.</span></div>
CY2024Q2	slrn	Concentration Risk Credit Risk Number Of Financial Institutions With Cash Deposits ConcentrationRiskCreditRiskNumberOfFinancialInstitutionsWithCashDeposits	1	institution
CY2022Q4	slrn	Asset Acquisition Number Of Subsidiaries Formed AssetAcquisitionNumberOfSubsidiariesFormed	2	subsidiary
CY2024Q2	slrn	Asset Acquisition Separately Recognized Transactions Severance Payable Current AssetAcquisitionSeparatelyRecognizedTransactionsSeverancePayableCurrent	0	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	613315000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	711588000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	613315000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	711588000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128211000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	218097000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	543000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128754000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	218097000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	613482000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	182000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	613315000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	711426000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	204000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	42000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	711588000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	1400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	800000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2024Q2	slrn	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	3379000	usd
CY2023Q4	slrn	Prepaid Research And Development Expenses Current PrepaidResearchAndDevelopmentExpensesCurrent	8184000	usd
CY2024Q2	slrn	Valued Added Tax Receivable Current ValuedAddedTaxReceivableCurrent	4136000	usd
CY2023Q4	slrn	Valued Added Tax Receivable Current ValuedAddedTaxReceivableCurrent	3985000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	2763000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1712000	usd
CY2024Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	1385000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	764000	usd
CY2024Q2	slrn	Prepaid Other Services Current PrepaidOtherServicesCurrent	1358000	usd
CY2023Q4	slrn	Prepaid Other Services Current PrepaidOtherServicesCurrent	667000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13021000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15312000	usd
CY2024Q2	slrn	Prepaid Research And Development Expense Noncurrent PrepaidResearchAndDevelopmentExpenseNoncurrent	291000	usd
CY2023Q4	slrn	Prepaid Research And Development Expense Noncurrent PrepaidResearchAndDevelopmentExpenseNoncurrent	2644000	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	34000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	34000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	325000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2678000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1735000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2294000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	226000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	115000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1509000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2179000	usd
CY2024Q2	slrn	Accrued Clinical Manufacturing Expenses Current AccruedClinicalManufacturingExpensesCurrent	24665000	usd
CY2023Q4	slrn	Accrued Clinical Manufacturing Expenses Current AccruedClinicalManufacturingExpensesCurrent	22232000	usd
CY2024Q2	slrn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	10452000	usd
CY2023Q4	slrn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	13204000	usd
CY2024Q2	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	35117000	usd
CY2023Q4	slrn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	35436000	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3965000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5417000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1259000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1099000	usd
CY2024Q2	slrn	Accrued Liabilities And Current Liabilities Other AccruedLiabilitiesAndCurrentLiabilitiesOther	255000	usd
CY2023Q4	slrn	Accrued Liabilities And Current Liabilities Other AccruedLiabilitiesAndCurrentLiabilitiesOther	317000	usd
CY2024Q2	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	5479000	usd
CY2023Q4	slrn	Accrued Compensation And Other Current Liabilities AccruedCompensationAndOtherCurrentLiabilities	6833000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	87900000	usd
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	142300000	usd
CY2024Q2	us-gaap	Loss On Contract Termination LossOnContractTermination	14300000	usd
CY2023Q1	slrn	Lessee Operating Lease Square Feet Leased LesseeOperatingLeaseSquareFeetLeased	10012	sqft
CY2023Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P65M
CY2023Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2023Q1	slrn	Lessee Operating Lease Monthly Payments LesseeOperatingLeaseMonthlyPayments	30500	usd
CY2023Q1	slrn	Lessee Operating Lease Annual Rent Increase Percent LesseeOperatingLeaseAnnualRentIncreasePercent	0.030
CY2023Q1	slrn	Lessee Operating Lease Rent Abatement Term LesseeOperatingLeaseRentAbatementTerm	P6M
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	34000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	34000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1300000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1300000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	189000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	386000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	398000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	409000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	280000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1662000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	353000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1309000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1069000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P50M
CY2024Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
	us-gaap	Variable Lease Payment VariableLeasePayment	200000	usd
CY2023Q2	slrn	Conversion Of Stock Ratio ConversionOfStockRatio	1
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24268800	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20101379	shares
CY2023Q2	slrn	Conversion Of Stock Ratio ConversionOfStockRatio	1
CY2020Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2839749	shares
CY2020Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.00002
CY2023Q2	slrn	Share Based Compensation Arrangement By Share Based Payment Award And Cash Based Compensation Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardAndCashBasedCompensationMaximum	750000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9630623	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.4619
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12007000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8602808	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.5348
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	215128	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.4375
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	50217	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.9078
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3241331	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.1166
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14726755	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.3731
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1922000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3510502	shares
CY2024Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	9.0101
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	880000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14726755	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.3731
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1922000	usd
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	12800000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.8440
CY2024Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	100827	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	100827	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8448
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8676
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7530
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9192
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8448
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8776
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7530
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9220
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0435
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0452
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0330
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0347
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0398
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0452
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0330
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0412
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10174000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8501000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30337000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15640000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10174000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8501000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30337000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15640000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-85672000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-26039000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-120645000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-202489000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	99215994	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	65652851	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	98653080	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	43461494	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	54284	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	442734	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	115395	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	486854	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99161710	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99161710	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	65210117	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65210117	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98537685	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98537685	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42974640	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42974640	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.71
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16883812	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10152817	shares
CY2024Q1	us-gaap	Other Nonrecurring Income OtherNonrecurringIncome	30000000.0	usd
CY2024Q1	slrn	Research And Development Expense Vendor Service Credit ResearchAndDevelopmentExpenseVendorServiceCredit	5000000.0	usd
	us-gaap	Other Nonrecurring Income OtherNonrecurringIncome	30000000	usd
	slrn	Research And Development Expense Vendor Service Credit ResearchAndDevelopmentExpenseVendorServiceCredit	5000000	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	7000000.0	usd
CY2024Q2	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	157500000	usd

Files In Submission

Name	View Source	Status
0001962918-24-000106-index-headers.html	Edgar Link	pending
0001962918-24-000106-index.html	Edgar Link	pending
0001962918-24-000106.txt	Edgar Link	pending
0001962918-24-000106-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slrn-20240630.htm	Edgar Link	pending
slrn-20240630.xsd	Edgar Link	pending
slrn-20240630x10qexx311.htm	Edgar Link	pending
slrn-20240630x10qexx312.htm	Edgar Link	pending
slrn-20240630x10qexx321.htm	Edgar Link	pending
slrn-20240630_def.xml	Edgar Link	unprocessable
slrn-20240630_lab.xml	Edgar Link	unprocessable
slrn-20240630_pre.xml	Edgar Link	unprocessable
slrn-20240630_htm.xml	Edgar Link	completed
slrn-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRN
ACELYRIN, Inc. Stock $slrn

2024 Q3 Form 10-Q Financial Statement

#000196291824000106 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRN ACELYRIN, Inc. Stock $slrn

2024 Q3 Form 10-Q Financial Statement

#000196291824000106 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRN
ACELYRIN, Inc. Stock $slrn